Related Experiment Video
Updated: Apr 4, 2026
10:53
Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
21.2K
Antiarrhythmic properties of beta-blockers
W Haverkamp1, G Hindricks, H Gülker
1Department of Cardiology-Angiology University of Münster, FRG.
Journal of Cardiovascular Pharmacology
|January 1, 1990
Summary
Beta-blockers effectively treat arrhythmias by suppressing sympathetic activity and slowing heart conduction. Their antifibrillatory effects in animal studies suggest improved survival for coronary artery disease patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers are established antiarrhythmic agents for supraventricular and ventricular arrhythmias.
- They counteract arrhythmias linked to sympathetic hyperactivity and modulate myocardial electrical activity.
Purpose of the Study:
- To review the antiarrhythmic efficacy of beta-blockers.
- To explore their role in preventing arrhythmias and improving survival in cardiovascular conditions.
Main Methods:
- Review of existing literature on beta-blocker mechanisms and clinical effects.
- Analysis of experimental data on antifibrillatory properties.
Main Results:
- Beta-blockers suppress automaticity and slow conduction in specific myocardial tissues.
- Animal studies demonstrate significant antifibrillatory effects post-coronary artery occlusion.
- Long-term beta-blockade correlates with improved survival in chronic coronary artery disease.
Conclusions:
- Optimal dosing is crucial to mitigate dose-related side effects.
- Beta-blockers show promise for broader antiarrhythmic application, potentially combined with other drug classes.
More Related Videos
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.9K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
01:28Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.1K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.7K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.7K